Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients.

Journal: Open forum infectious diseases
Published Date: Sep 30, 2020

Abstract

BACKGROUND: The efficacy of nucleot(s)ide analogs (NAs) and pegylated interferon (PegIFN) combination therapy for hepatitis B e antigen-positive (HBeAg) patients is still controversial. Whether PegIFN and entecavir (ETV) combination therapy could provide a greater benefit for HBeAg patients was assessed.

Authors

  • Lu Chen
    Ultrasonic Department, Zhongda Hospital Affiliated to Southeast University, Nanjing, 210009, China.
  • Lanyi Lin
    Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Huijuan Zhou
    Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Weiliang Tang
    Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Hui Wang
    Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Wei Cai
    Department of Gastrointestinal Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Shisan Bao
    Discipline of Pathology, School of Medical Science, Charles Perkins Centre, The Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Simin Guo
    Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Qing Xie
    Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals